MedTrace Logo

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-11-22

No results posted yet for this study

Summary

A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo.

Subjects must have been enrolled in a prior IDN-6556 study to be eligible.

Conditions

  • Liver Diseases
  • Liver Fibrosis
  • Liver Cirrhosis
  • NASH Fibrosis
  • Decompensated Non-Alcoholic Steatohepatitis Cirrhosis
  • Orthotopic Liver Transplantation

Interventions

DIAGNOSTIC_TEST

Ultrasound

Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.

Sponsors & Collaborators

  • Conatus Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Mason Yamashita, MD · Conatus Pharmaceuticals Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2019-08-31
Completion
2019-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03479125 on ClinicalTrials.gov